Axicabtagene-ciloleucel: Immune effector cell-associated neurotoxicity and cytokine release syndrome: 2 case reports.

It was noted that his neurotoxicity symptoms occurred before dexamethasone was added for cytokine release syndrome treatment. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a study, two men aged 53-70 years were described, who developed immune effector cell-associated neurotoxicity (ICANS) and cytokine release syndrome (CRS) during treatment with axicabtagene ciloleucel [ I dosages not stated; not all outcomes and durations of treatments to reactions onsets not stated i ]. [Extracted from the article]